OncoSec Medical to Present at “TEN”; Noble Financial Capital Markets’ Tenth Annual Equity Conference

Noble Financial Capital Markets’ Tenth Annual Equity Conference

SAN DIEGO--()--OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present at “TEN”; Noble Financial Capital Markets’ Tenth Annual Equity Conference, at Club Med in Sandpiper Bay, Florida, on Tuesday, January 21 at 1:30 p.m. (EST) in Room 1.

At the time of the presentation, a live audio and high-definition video webcast of OncoSec’s presentation will be available at the following link: http://noble.mediasite.com/mediasite/Play/43f884803e304fcabf7f2cca45be07d51d

OncoSec recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. Participants will require a Microsoft Silverlight viewer (a free download from the presentation link) in order to participate.

About Noble Financial Capital Markets

Noble Financial Capital Markets was established in 1984; 2014 marks its 30th Anniversary. Noble Financial is an equity research driven, full-service, investment banking boutique focused on life sciences, technology and media, emerging growth, companies. The company has offices in Boston, Los Angeles, and Boca Raton, FL. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in January in South Florida featuring 120 - 150 presenting companies from across North America and total attendance of close to 600. For more information: www.noblefcm.com

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that can minimize the detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while potentially sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contacts

OncoSec Medical Inc.
Investor Relations:
Amy Chan, 855-662-6732
investors@oncosec.com

Contacts

OncoSec Medical Inc.
Investor Relations:
Amy Chan, 855-662-6732
investors@oncosec.com